Moderna and Pfizer May Benefit From This Rival’s Bad News – Nasdaq

Published

CureVac (NASDAQ: CVAC) recently reported disappointing efficacy data from the phase 3 trial of its coronavirus vaccine candidate. The company expects more data and then will decide on what to do next. In this Motley Fool Live video recorded on June 22, healthcare and cannabis bureau editor and analyst Olivia Zitkus and Fool.com contributor Adria Cimino discuss what a potential win means for CureVac — and how a potential loss may help today’s vaccine leaders.

10 stocks we like better than Moderna Inc.

When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now… and Moderna Inc. wasn’t one of them! That’s right — they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of June 7, 2021

Olivia Zitkus: Is CureVac still looming large as a potential player in the general vaccine space? Has the company signed any other major purchase agreements that investors are still holding onto for some hope here?

Adria Cimino: As a matter of fact, they have. It could be a big player in Europe. They signed a deal in Europe for as many as 405 million doses. That includes the option for more doses, so that will be a total of at maximum 405 million doses. They can be a pretty good provider in Europe. We’ll have to see if that’s going to go through or not depending on what happens with the final analysis. Now, if this falls through, this might be positive news for Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) because chances are Europe is looking for more doses. Europe has struggled with supply issues and got behind in vaccinations and everything. It’s very possible that if the CureVac deal falls through, they’re going to be looking for more doses elsewhere. Then, of course, we have Pfizer and Moderna ready to provide them. It very well could be good news for Pfizer and Moderna or maybe even Novavax down the road.

Adria Cimino has no position in any of the stocks mentioned. Olivia Zitkus owns shares of Moderna Inc. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MRNA PFE CVAC

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world’s greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company’s name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king — without getting their heads lopped off.

Learn More